Home / Health / Thyroid Med Recall: Less Potent Tablets Nationwide
Thyroid Med Recall: Less Potent Tablets Nationwide
27 Jul
Summary
- Major Pharmaceuticals recalled levothyroxine tablets nationwide.
- Tablets are subpotent, potentially containing less active ingredient.
- Recall is Class II, posing a risk of temporary health consequences.
A nationwide recall of levothyroxine sodium tablets has been voluntarily initiated by Major Pharmaceuticals. This recall, effective as of July 13, encompasses twelve product lines across seven dosage strengths. The concern stems from the possibility that the tablets are subpotent, containing less active thyroid hormone than specified.
Subpotency in levothyroxine can significantly impact patients managing hypothyroidism. Insufficient hormone levels may allow symptoms like fatigue and cognitive difficulties to persist or escalate. Patients who believe they may have received affected medication are urged to contact their healthcare providers for guidance.
The Food and Drug Administration has classified this recall as Class II. This classification indicates that while the subpotent medication could lead to temporary or medically reversible adverse health effects, the probability of serious harm is considered remote. Pharmacies and healthcare providers are instructed to quarantine any distributed affected lots.
